A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy

Narcolepsy With Cataplexy Clinical Trial

Official title:

A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03030599
• Other study ID #: 15-006
• Secondary ID: 2016-000426-20
• Status: Completed
• Phase: Phase 3
• Start date: March 14, 2017
• Est. completion date: July 10, 2019

Study information

• Verified date: November 2020
• Source: Jazz Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, placebo-controlled, randomized-withdrawal, multicenter study of the efficacy and safety of JZP-258.

Description:

Subjects will be transitioned to JZP-258 based on their treatment status at study entry. All subjects will begin JZP-258 treatment at the beginning of this period and continue through Week 12. They will be treated with JZP-258 alone for the final two weeks of this 12-week period. Once the JZP-258 dose has been optimized per the Investigator's judgment, these subjects may enter the 2-week Stable-Dose Period with that dose. Subjects are eligible to enter the Double-Blind Randomized-Withdrawal Period if the dose of JZP-258 remains unchanged during the Stable-Dose Period and, in the judgment of the Investigator, no clinically significant worsening in narcolepsy symptoms or clinically significant adverse events due to JZP-258 treatment have occurred. Subjects will return for a Safety Follow-up visit 2 weeks after the Double-Blind Randomized-Withdrawal Period. Subjects who complete the double-blind treatment period during the Main Study are eligible to enter a 24-week Open-Label Extension. During this period subjects will receive open label JZP-258. Subjects will return for a Safety Follow-up visit 2 weeks after the Open-Label Extension Period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 201
• Est. completion date: July 10, 2019
• Est. primary completion date: January 24, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Male or female subjects between 18 and 70 years of age, inclusive.

2. Have a primary diagnosis of narcolepsy with cataplexy that meets ICSD-3 criteria or DSM-5 criteria, and currently untreated or treated with or without anticataplectics.

3. If applicable, treated with a stimulant or alerting agent at unchanged doses for at least 2 months prior to dosing or not treated with a stimulant or alerting agent.

4. Willing and able to comply with the study design schedule and other requirements.

5. Willing and able to provide written informed consent.

Exclusion Criteria:

1. Narcolepsy secondary to another medical condition (e.g., CNS injury or lesion)

2. History or presence of any unstable or clinically significant medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or history or presence of another neurological disorder or surgical history that might affect the subject's safety and/or interfere with the conduct of the study in the opinion of the Investigator.

3. Treatment with any central nervous system sedating agents, including but not limited to benzodiazepines, nonbenzodiazepine anxiolytics/ hypnotics/sedatives, neuroleptics, opioids, barbiturates, phenytoin, ethosuximide, or MCT inhibitors, e.g. diclofenac, valproate, ibuprofen, within 2 weeks prior to enrollment (discontinuation for the purpose of study enrollment is permitted only if considered safe by the Investigator and approved by the Medical Monitor).

4. Treatment with an antidepressant for cataplexy, if the withdrawal of the antidepressant during cross-titration with JZP-258 might be unsafe due to prior history of depression.

5. Unsafe for the subject to receive placebo treatment for 2 weeks, in the opinion of the Investigator.

Related Conditions & MeSH terms

• Cataplexy
• Narcolepsy
• Narcolepsy With Cataplexy

Intervention

Drug:
• JZP-258
JZP-258 oral solution 0.5 g/mL, which is equivalent to 0.413 g/mL of oxybate

Other:
• Placebo
Matching placebo solution (aqueous solution containing sodium citrate, malic acid, and sucralose; all ingredients were compendial [United States Pharmacopeia/ National Formulary])

Locations

Country	Name	City	State
Belgium	UZ Antwerpen	Edegem
Belgium	Universitair Ziekenhuis Gent	Gent
Belgium	UZ Leuven	Leuven
Czechia	Fakultni nemocnice Ostrava	Ostrava-Poruba
Czechia	Vseobecna fakultni nemocnice v Praze	Praha 2
Finland	Helsingin Uniklinikka, Vitalmed Oy	Helsinki
France	Hopital Roger Salengro - CHU Lille	Lille
France	Hôpital Gui de Chauliac	Montpellier	Herault
Spain	Hospital Clinic i Provincial de Barcelona	Barcelona
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Hospital General de Castellón	Castelló
Spain	Hospital Vithas Nuestra Señora de America	Madrid
Spain	Instituto de Investigaciones del Sueño	Madrid
United States	Colorado Sleep Institute	Boulder	Colorado
United States	Montefiore/ Sleep-Wake Disorders Center	Bronx	New York
United States	Center for Sleep & Wake Disorders	Chevy Chase	Maryland
United States	Intrepid Research	Cincinnati	Ohio
United States	Cleveland Clinic, Sleep Disorder Center	Cleveland	Ohio
United States	Fort Wayne Neurological Center	Fort Wayne	Indiana
United States	Gastonia Medical Specialty Clinic	Gastonia	North Carolina
United States	Research Carolina	Huntersville	North Carolina
United States	Pulmonary Disease Specialists	Kissimmee	Florida
United States	Kentucky Research Group	Louisville	Kentucky
United States	SDS Clinical Trials, Inc.	Orange	California
United States	Stanford Health Services	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Jazz Pharmaceuticals

Countries where clinical trial is conducted

United States,  Belgium,  Czechia,  Finland,  France,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Weekly Number of Cataplexy Attacks	Participants completed a daily Cataplexy Frequency Diary each night prior to bedtime. Participants were to record the number of cataplexy attacks that they had each day.	Change from baseline (2 weeks of the Stable Dose Period) to the 2 weeks of the Double Blind Randomized Withdrawal Period (DB RWP)
Secondary	Change in the Epworth Sleepiness Scale (ESS) Score	This is the key secondary endpoint. The Epworth Sleepiness Scale (ESS) was a self-administered questionnaire with 8 questions. Participants were asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most participants engaged in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that participants average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.	From the end of the Stable Dose Period to the end of the Double Blind Randomized Withdrawal Period
Secondary	Number of Participants With Worsening Patient Global Impression of Change (PGIc) for Narcolepsy Overall	At the end of the Double Blind Randomized Withdrawal Period (DB RWP), participants rated the change in their condition on a 7-point scale ranging from 1 = "very much improved" to 7 = "very much worse" since the last visit. This endpoint measures the percentage of participants with worsening PGIc scores for narcolepsy overall (defined as scores of Much Worse or Very Much Worse).	At the end of the Double Blind Randomized Withdrawal Period
Secondary	Number of Participants With Worsening Clinical Global Impression of Change (CGIc) for Narcolepsy Overall	At the end of the Double Blind Randomized Withdrawal Period, Investigators rated their impression of any change in the severity of the participant's narcolepsy overall condition since the start of the Double Blind Randomized Withdrawal Period on a 7-point scale ranging from 1 = "very much improved" to 7 = "very much worse". This endpoint measures the percentage of participants with worsening CGIc scores for narcolepsy overall, defined as scores of Much Worse or Very Much Worse.	At the end of the Double Blind Randomized Withdrawal Period
Secondary	Change in 36-Item Short Form Health Survey Version 2 (SF-36v2) Scores	The SF-36v2 is a multi-purpose, short-form health survey with 36 questions/ items. It yields an 8-scale profile of functional health and well-being scores as well as a psychometrically-based physical and mental overall component summary measures. Two summary scores were derived using the SF-36v2. Physical Component Summary measures dimensions of functional health that are meaningful to respondents, including the impact of health and health-related changes on physical function, pain, and the ability to carry out daily roles. The Mental Component Summary component scale measures the impact of health and health-related changes on well-being, including vitality, social function, and emotional well-being. Participants self-report on items in a summary that have between 2-6 choices per item (e.g. none of the time, some of the time, etc.). Summations of item scores were transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.	At the End of the Stable Dose Period to the End of the Double Blind Randomized Withdrawal Period
Secondary	Change in 5-level EQ-5D (EQ-5D-5L) Crosswalk Index Score and Visual Analog Scale	The EQ-5D-5L is a measure of health outcome that includes a descriptive system consisting of 5 dimensions (mobility, self-care, usual activities, pain/ discomfort, and anxiety/ depression). The EQ-5D-5L includes 5 levels of severity for each of the 5 dimensions of the descriptive system (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, and 5= extreme problems) that reflect increasing levels of difficulty. The 5 digit health states for each dimension are converted into a single value per country (0= equivalent to death, 1= equivalent to best imaginable health and values below 0= health states rated worse than death capped at -1), using the EQ-5D-5L crosswalk index value calculator as recommended by EuroQol group. A visual analogue scale (VAS) used within this scale recorded the participants self-rated health on a VAS and the endpoints resulted in a numeric value set ranging from 0 (= worst imaginable health state) up to 100 (= best imaginable health state).	At the End of the Stable Dose Period to the End of the Double Blind Randomized Withdrawal Period